Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, commonly referred to as Medigen or MVC, is a Taiwan-based pharmaceutical and biotechnology company focused on vaccine and biologics development. The company was established in October 2012 and is headquartered in Taipei's Neihu District. Its corporate identity is closely associated with the development of vaccines intended for infectious-disease prevention, including the MVC COVID-19 vaccine developed during Taiwan's response to the COVID-19 pandemic. Medigen's most visible public role emerged during the pandemic, when Taiwan sought to expand domestic vaccine capabilities and reduce reliance on imported supplies. The company developed the MVC COVID-19 vaccine for use in Taiwan, making it one of the local biotechnology companies involved in the country's domestic COVID-19 vaccine effort. The product became the principal known expression of the Medigen brand and placed the company within Taiwan's public-health, pharmaceutical, and biotechnology sectors. In addition to vaccine development, Medigen operates manufacturing infrastructure at the Hsinchu Biomedical Science Park in Zhubei City, Hsinchu County. This facility supports the company's positioning as an integrated vaccine and biologics organization rather than solely a research-stage developer. Its activities therefore span product research and development, clinical and regulatory work, and manufacturing capabilities. The company has also pursued activity outside Taiwan. In March 2026, Vietnam's Ministry of Health approved the rollout of Medigen's enterovirus vaccine in Vietnam. This approval was described as the company's first overseas rollout, representing an international expansion milestone beyond its domestic Taiwanese market. The available reference material does not establish the full commercial scale of that rollout, the exact launch date, or the breadth of subsequent overseas distribution. Medigen's current brand positioning is consequently centered on locally developed vaccines, biologics expertise, and the conversion of Taiwan-based research and manufacturing capabilities into products for domestic and international use. Publicly documented information supplied for this dossier does not identify a founder, parent company, owner, current executives, stock ticker, detailed revenue history, or a complete catalog of commercial products. Those fields remain unassigned rather than inferred.

Medigen Vaccine Biologics Corporation was founded in October 2012 in Taiwan. The company was created as a pharmaceutical and biotechnology enterprise with a focus on vaccines and biologics. It established its headquarters in Taipei's Neihu District and developed manufacturing capability at the Hsinchu Biomedical Science Park in Zhubei City, Hsinchu County. The COVID-19 pandemic became the defining early public milestone for the Medigen brand. During Taiwan's pandemic response, Medigen developed the MVC COVID-19 vaccine as part of the country's effort to build domestic vaccine capacity. The vaccine gave the company a prominent role in Taiwan's biotechnology and public-health landscape and made Medigen one of the most recognizable local vaccine developers. The supplied reference material does not provide enough detail to establish the vaccine's complete clinical-development timeline, regulatory pathway, procurement history, or distribution volumes, so those matters are not expanded here. Medigen's manufacturing presence in Hsinchu Biomedical Science Park is an important part of its corporate profile. It indicates that the company has pursued capabilities extending beyond discovery and laboratory research into the production of vaccine and biologics products. The available material does not specify the facility's capacity, technologies, certifications, or product-by-product manufacturing allocation. The company later began extending its vaccine activities outside Taiwan. On 18 March 2026, Vietnam's Ministry of Health approved the rollout of Medigen's enterovirus vaccine. The approval was reported as Medigen's first overseas rollout, providing a significant internationalization milestone for a company whose best-known public activities had previously been associated with Taiwan. The available sources do not establish the size of the Vietnamese program, its commercial terms, or whether additional foreign markets had been approved by the date of the reference. As documented in the available material, Medigen's history is therefore defined by its 2012 founding, the development of the MVC COVID-19 vaccine during the pandemic, the creation of manufacturing infrastructure in Hsinchu County, and the 2026 Vietnamese approval of its enterovirus vaccine. Information about subsequent corporate leadership, ownership, financial performance, additional product launches, and broader international operations is not available in the supplied references.

1. 2026First overseas vaccine rollout approved

   Vietnam's Ministry of Health approved the rollout of Medigen's enterovirus vaccine, described as the company's first overseas rollout.

   Source
2. 2012Company founded

   Medigen Vaccine Biologics Corporation was founded in Taiwan in October 2012.

   Source
3. Hsinchu manufacturing facility established

   Medigen operates a manufacturing plant at the Hsinchu Biomedical Science Park in Zhubei City, Hsinchu County.

   Source

A Taiwan-based vaccine and biologics company emphasizing domestic development, manufacturing capability, and expansion into overseas vaccine markets.

• MVC COVID-19 vaccineCOVID-19 vaccine

  The MVC COVID-19 vaccine is Medigen's best-known pandemic-era product. It was developed during Taiwan's COVID-19 response and represented the company's contribution to domestic vaccine development. The available reference material identifies the product and its public-health purpose but does not provide a complete technical description, development chronology, dosage information, or current commercial status.

• Medigen enterovirus vaccineEnterovirus vaccine2026

  Medigen's enterovirus vaccine received approval from Vietnam's Ministry of Health for rollout in March 2026. The approval was described as the company's first overseas rollout. The supplied sources do not specify the precise enterovirus target, formulation, launch volume, or the full set of markets in which the product may be available.

• 2026Pursued first overseas rollout through VietnamProduct launch

  After developing vaccine products in Taiwan, Medigen sought to extend its international reach through regulatory approval in Vietnam for its enterovirus vaccine.

  What changed. Vietnam's Ministry of Health approved the rollout of the Medigen enterovirus vaccine.

  Aftermath. The approval was identified as Medigen's first overseas rollout and established Vietnam as an international market for the company's vaccine portfolio.

  Source

• 2026Vietnam approves rollout of Medigen enterovirus vaccine

  Vietnam's Ministry of Health approved the rollout of Medigen's enterovirus vaccine. The approval was identified as the company's first overseas rollout and marked an expansion beyond its Taiwanese home market.

  Product launchRegulation
  Source

1. Medigen Vaccine Biologics Corporation
2. Medigen Vaccine Biologics official website